Crossmark

Single cell transcriptomics reveals distinct transcriptional responses to oxycodone and buprenorphine by iPSC-derived brain organoids from patients with opioid use disorder

Crossref DOI link: https://doi.org/10.1038/s41380-022-01837-8

Published Online: 2022-10-27

Published Print: 2024-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ho, Ming-Fen https://orcid.org/0000-0002-3757-3924
Zhang, Cheng

Moon, Irene

Zhu, Xiujuan

Coombes, Brandon J. https://orcid.org/0000-0003-4322-5923
Biernacka, Joanna https://orcid.org/0000-0001-9350-4440
Skime, Michelle https://orcid.org/0000-0001-7863-3017
Oesterle, Tyler S. https://orcid.org/0000-0002-7363-8086
Karpyak, Victor M. https://orcid.org/0000-0002-9552-6130
Schmidt, Kristen

Gliske, Kate

Ngo, Quyen

Skillon, Cedric

Seppala, Marvin D.

Li, Hu https://orcid.org/0000-0001-5957-5472
Weinshilboum, Richard M. https://orcid.org/0000-0002-4911-7985
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (AA28050, AA27486)

U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism
License Information

Text and Data Mining valid from 2022-10-27

Version of Record valid from 2022-10-27
More Information

Article History

Received: 2 May 2022

Revised: 4 October 2022

Accepted: 10 October 2022

First Online: 27 October 2022

Competing interests

: RMW is a cofounder of and stockholder in OneOme LLC, a pharmacogenomics decision-support company. All other authors have no conflicts to declare.

Document is current

Any future updates will be listed below